Duration of antipsychotic medication use by aged care facility residents with dementia

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Introduction: Guidelines recommend short-term targeted use of antipsychotic medications for behavioral and psychological symptoms of dementia only when other strategies have failed. Antipsychotic prescribing in dementia is common internationally, but data on duration of use are limited. Our objectives were to determine duration, time to initiation, and prevalence of antipsychotic use among people with dementia. Methods: This work was a retrospective dynamic cohort study of people aged 65 years or above with dementia in 68 residential aged facilities during the period spanning from 2014 to 2017. Medication administration records were used to identify antipsychotic medication use. Medication outcomes (prevalence, duration, and time to initiation) were estimated using regression. Covariates included comorbidities and sociodemographic and facility characteristics. Results: A total of 5825 residents with dementia were identified. The annual prevalence of antipsychotic use ranged from 27.6% to 32.6%. Mean time to initiation after admission was 308.4 days (for female individuals) and 173.2 days (for male individuals). An overall 65% of people who used antipsychotics did so for >3 months even without psychiatric comorbidities; mean durations were 212.74 (95% confidence interval: 170.24, 255.25) days (for female individuals) and 216.10 (95% confidence interval: 165.31, 266.89) days (for male individuals) at median ages. Discussion: Antipsychotics are often used longer than recommended. Current guidelines and restrictions may be insufficient to limit antipsychotic medication use. Further efforts are needed to ensure that antipsychotic medications are used as recommended in dementia.
LanguageEnglish
Pages331-338
Number of pages8
JournalAlzheimer Disease and Associated Disorders
Volume33
Issue number4
Early online date22 Jul 2019
DOIs
Publication statusPublished - Dec 2019

Fingerprint

Antipsychotic Agents
Dementia
Comorbidity
Residential Facilities
Guidelines
Confidence Intervals
Behavioral Symptoms
Psychiatry
Cohort Studies
Psychology

Keywords

  • BPSD
  • dementia
  • antipsychotic medication

Cite this

@article{08bf469fb50846c8a6de3e3078d8b4f9,
title = "Duration of antipsychotic medication use by aged care facility residents with dementia",
abstract = "Introduction: Guidelines recommend short-term targeted use of antipsychotic medications for behavioral and psychological symptoms of dementia only when other strategies have failed. Antipsychotic prescribing in dementia is common internationally, but data on duration of use are limited. Our objectives were to determine duration, time to initiation, and prevalence of antipsychotic use among people with dementia. Methods: This work was a retrospective dynamic cohort study of people aged 65 years or above with dementia in 68 residential aged facilities during the period spanning from 2014 to 2017. Medication administration records were used to identify antipsychotic medication use. Medication outcomes (prevalence, duration, and time to initiation) were estimated using regression. Covariates included comorbidities and sociodemographic and facility characteristics. Results: A total of 5825 residents with dementia were identified. The annual prevalence of antipsychotic use ranged from 27.6{\%} to 32.6{\%}. Mean time to initiation after admission was 308.4 days (for female individuals) and 173.2 days (for male individuals). An overall 65{\%} of people who used antipsychotics did so for >3 months even without psychiatric comorbidities; mean durations were 212.74 (95{\%} confidence interval: 170.24, 255.25) days (for female individuals) and 216.10 (95{\%} confidence interval: 165.31, 266.89) days (for male individuals) at median ages. Discussion: Antipsychotics are often used longer than recommended. Current guidelines and restrictions may be insufficient to limit antipsychotic medication use. Further efforts are needed to ensure that antipsychotic medications are used as recommended in dementia.",
keywords = "BPSD, dementia, antipsychotic medication",
author = "Lind, {Kimberly E.} and Raban, {Magdalena Z.} and Andrew Georgiou and Westbrook, {Johanna I.}",
year = "2019",
month = "12",
doi = "10.1097/WAD.0000000000000336",
language = "English",
volume = "33",
pages = "331--338",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "NIH Public Access",
number = "4",

}

TY - JOUR

T1 - Duration of antipsychotic medication use by aged care facility residents with dementia

AU - Lind, Kimberly E.

AU - Raban, Magdalena Z.

AU - Georgiou, Andrew

AU - Westbrook, Johanna I.

PY - 2019/12

Y1 - 2019/12

N2 - Introduction: Guidelines recommend short-term targeted use of antipsychotic medications for behavioral and psychological symptoms of dementia only when other strategies have failed. Antipsychotic prescribing in dementia is common internationally, but data on duration of use are limited. Our objectives were to determine duration, time to initiation, and prevalence of antipsychotic use among people with dementia. Methods: This work was a retrospective dynamic cohort study of people aged 65 years or above with dementia in 68 residential aged facilities during the period spanning from 2014 to 2017. Medication administration records were used to identify antipsychotic medication use. Medication outcomes (prevalence, duration, and time to initiation) were estimated using regression. Covariates included comorbidities and sociodemographic and facility characteristics. Results: A total of 5825 residents with dementia were identified. The annual prevalence of antipsychotic use ranged from 27.6% to 32.6%. Mean time to initiation after admission was 308.4 days (for female individuals) and 173.2 days (for male individuals). An overall 65% of people who used antipsychotics did so for >3 months even without psychiatric comorbidities; mean durations were 212.74 (95% confidence interval: 170.24, 255.25) days (for female individuals) and 216.10 (95% confidence interval: 165.31, 266.89) days (for male individuals) at median ages. Discussion: Antipsychotics are often used longer than recommended. Current guidelines and restrictions may be insufficient to limit antipsychotic medication use. Further efforts are needed to ensure that antipsychotic medications are used as recommended in dementia.

AB - Introduction: Guidelines recommend short-term targeted use of antipsychotic medications for behavioral and psychological symptoms of dementia only when other strategies have failed. Antipsychotic prescribing in dementia is common internationally, but data on duration of use are limited. Our objectives were to determine duration, time to initiation, and prevalence of antipsychotic use among people with dementia. Methods: This work was a retrospective dynamic cohort study of people aged 65 years or above with dementia in 68 residential aged facilities during the period spanning from 2014 to 2017. Medication administration records were used to identify antipsychotic medication use. Medication outcomes (prevalence, duration, and time to initiation) were estimated using regression. Covariates included comorbidities and sociodemographic and facility characteristics. Results: A total of 5825 residents with dementia were identified. The annual prevalence of antipsychotic use ranged from 27.6% to 32.6%. Mean time to initiation after admission was 308.4 days (for female individuals) and 173.2 days (for male individuals). An overall 65% of people who used antipsychotics did so for >3 months even without psychiatric comorbidities; mean durations were 212.74 (95% confidence interval: 170.24, 255.25) days (for female individuals) and 216.10 (95% confidence interval: 165.31, 266.89) days (for male individuals) at median ages. Discussion: Antipsychotics are often used longer than recommended. Current guidelines and restrictions may be insufficient to limit antipsychotic medication use. Further efforts are needed to ensure that antipsychotic medications are used as recommended in dementia.

KW - BPSD

KW - dementia

KW - antipsychotic medication

UR - http://purl.org/au-research/grants/arc/LP120200814

UR - http://purl.org/au-research/grants/nhmrc/1143941

UR - http://www.scopus.com/inward/record.url?scp=85075487899&partnerID=8YFLogxK

U2 - 10.1097/WAD.0000000000000336

DO - 10.1097/WAD.0000000000000336

M3 - Article

VL - 33

SP - 331

EP - 338

JO - Alzheimer Disease and Associated Disorders

T2 - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 4

ER -